Linda Yaccarino has joined eMed Population Health as CEO, aiming to enhance their population health management platform for GLP-1 drugs. The digital health company, which raised $22 million by 2022, seeks to leverage technology and data in healthcare. Yaccarino emphasizes the partial disruption of the healthcare industry by technology and highlights the potential to innovate through digital channels. Goldman Sachs predicts significant growth in the anti-obesity drug market, with 15 million U.S. adults expected to use these drugs by 2030, potentially generating $100 billion in revenue.
"The healthcare industry has been disrupted by technology, but not yet completely transformed by it. There is an opportunity to combine technology, lifestyle, and data in a new powerful way through the digital channels that impact consumers directly in ways that have never been done before."
"To be a leader in today's healthcare marketplace, companies need to have a fearless tenacity that allows them to not only grow, but to also be brave enough to step forward and redefine an entire industry."
Collection
[
|
...
]